The 22 references in paper S. Avdeev N., С. Авдеев Н. (2015) “Обострения хронической обструктивной болезни легких: выбор антибактериальной терапии // Exacerbation of chronic obstructive pulmonary disease: a choice of antibacterial treatment” / spz:neicon:pulmonology:y:2014:i:6:p:65-72

1
Hurst J.R., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med.2010; 363: 1128–1138.
(check this in PDF content)
2
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. Last updated 2014. www.goldcopd.org
(check this in PDF content)
3
Stanford R.H., Shen Y., McLaughlin T. Cost of chronic obstructive pulmonary disease in the emergency department and hospital: an analysis of administrative data from 218 US hospitals. Treat. Respir. Med.2006; 5: 343–349.
(check this in PDF content)
4
O'Donnell D.E., Parker C.M. COPD exacerbations: Pathophysiology. Thorax. 2006; 61: 354–361. Группы терапии Плацебо АMK 1,0 0,8 0,6 0,4 0,2 0,0 0 100 200 300 400 Дни после начала исследования Интервал, свободный от обострений 233 дня 160 дней p = 0,015 Рис. 3. Период до следующего обострения при терапии обострений ХОБЛ с использованием АМК и плацебо Fig. 3. Time to the first exacerbation in patients treated with amoxicilline / clavulanate or placebo for COPD exacerbation 70Пульмонология 6’2014
(check this in PDF content)
5
Donaldson G.C., Seemungal T.A.R., Bhowmik A., Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002; 57: 847–852.
(check this in PDF content)
6
Seemungal T.A.R., Donaldson G.C., Paul E.A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.Am. J. Respir. Crit. Care Med. 1998; 151: 1418–1422.
(check this in PDF content)
7
Miravitlles M., Murio C., Guerrero T. et al. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest. 2002; 121: 1449–1455.
(check this in PDF content)
8
Celli B.R., Barnes P.J. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Eur. Respir. J.2007; 29: 1224–1238.
(check this in PDF content)
9
Seneff M.G., Wagner D.P., Wagner R.P. et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease.JAMA.1995; 274: 1852–1857. 23. Celli B.R., MacNee W. ATS / ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper.Eur. Respir. J. 2004; 23: 932–946. 24. Dev D., Sankaran E.W.R., Cunnife J. et al. Value of C-reactive protein in exacerbation of chronic obstructive pulmonary disease.Respir. Med.1998; 92: 664–667. 25. Авдеев С.Н., Баймаканова Г.Е., Зубаирова П.А. Возможности С-реактивного белка в диагностике бактериальной инфекции и пневмонии у больных с обострением хронической обструктивной бол
(check this in PDF content)
10
Connors A.F. Jr, Dawson N.V., Thomas C. et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am. J. Respir. Crit. Care Med. 1996; 154: 959–967.
(check this in PDF content)
11
Wouters E.F. The burden of COPD in The Netherlands: results from the Confronting COPD survey. Respir. Med. 2003; 97 (Suppl. C): S51–59.
(check this in PDF content)
12
Gunen H., Hacievliyagil S.S., Kosar F. et al. Factors affecting survival of hospitalised patients with COPD. Eur. Respir. J. 2005; 26: 234–241.
(check this in PDF content)
13
Kong G.K., Belman M.J., Weingarten S. Reducing length of stay for patients hospitalized with exacerbation of COPD by using a practice guideline. Chest. 1997; 111: 89–94.
(check this in PDF content)
14
Han M.K., Agusti A., Calverley P.M. et al. COPD phenotypes: The future of COPD.Am. J. Respir. Crit. Care Med. 2010; 182: 598–604.
(check this in PDF content)
15
Bafadhel M., McKenna S., Terry S. et al. Acute exacerbations of chronic obstructive pulmonary disease. Identification of biologic clusters and their biomarkers. Am. J. Respir. Crit. Care Med. 2011; 184: 662–671.
(check this in PDF content)
16
Aaron S.D., Donaldson G.C., Whitmore G.A. et al. Time course and pattern of COPD exacerbation onset. Thorax. 2012; 67: 238–243.
(check this in PDF content)
17
Papi A., Bellettato C.M., Braccioni F. et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 2006; 173: 1114–1121.
(check this in PDF content)
18
Veeramachaneni S.B., Sethi S. Pathogenesis of bacterial exacerbations of COPD. COPD. 2006; 3: 109–115.
(check this in PDF content)
19
Eller J., Ede A., Schaberg T. et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest. 1998; 113: 1542–1548.
(check this in PDF content)
20
Hirschmann J.V. Do bacteria cause exacerbations of COPD? Chest. 2000; 118: 193–203.
(check this in PDF content)
21
Anthonisen N.R., Manfreda J., Warren C.P. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med.1987; 106: 196–204.
(check this in PDF content)
22
Roede B.M., Bresser P., El Moussaoui R. et al. Three vs. 10 days of amoxycillin-clavulanic acid for type 1 acute exacerbations of chronic obstructive pulmonary disease: a randomised, double-blind study.Clin. Microbiol. Infect. 2007; 13: 284–290. http:// journal.pul
(check this in PDF content)